

Scott-Edil Pharmacia Limited

December 19, 2017

Summary of rated instruments

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Cash Credit	50.0	50.0	[ICRA]BBB (Stable) ISSUER NOT COOPERATING withdrawn
Term Loans	1.8	1.8	[ICRA]BBB (Stable) ISSUER NOT COOPERATING withdrawn
LC/FLC	25.0	25.0	[ICRA]A3+ ISSUER NOT COOPERATING withdrawn
Bank Guarantee*	(12.0)	(12.0)	[ICRA]A3+ ISSUER NOT COOPERATING withdrawn
Total	76.8	76.8	

*Sub-Limit of LC

Rating action

ICRA has withdrawn the ratings of [ICRA]BBB (Stable)/A3+ ISSUER NOT COOPERATING assigned to the Rs. 76.8 crore¹ bank facilities of Scott-Edil Pharmacia Limited (SEPL or the company)².

Rationale

The ratings have been withdrawn basis the request of company and in accordance with ICRA's policy on withdrawal and suspension.

Outlook: Not Applicable

Analytical approach: For arriving at the ratings, ICRA has applied its rating methodologies as indicated below.

Links to applicable criteria:

[Corporate Credit Rating Methodology](#)

[ICRA Policy on Withdrawal and Suspension of Credit Rating](#)

¹ 100 lakh = 1 crore = 10 million

² For complete rating scale and definitions, please refer to ICRA's website www.icra.in or other ICRA Rating Publications

About the company

Scott-Edil Pharmacia Limited, established in 2003, is a privately held company with 100% shareholding by the promoters. The company is engaged in pharmaceuticals contract manufacturing for Indian pharmaceutical companies and government institutions. In addition to this, SEPL also has some in-house brands that it promotes in the domestic market as well as some semi-regulated export markets. It has a World Health Organization – Good Manufacturing Practices certified manufacturing facility present in Jharmajri Baddi in Himachal Pradesh.

Scott-Edil Advance Research Laboratories and Education Limited (SEARLE), an associate company of SEPL, was established in 2011 for tapping clients in the regulated markets of USA, UK and Europe. However, as the company is still awaiting approvals from the US FDA and other regulatory authorities, it currently undertakes contract manufacturing of generic drug formulations for domestic pharmaceutical companies and own-branded generic drug formulations for the domestic and semi-regulated export markets. The manufacturing facility of SEARLE is present in Baddi, Himachal Pradesh.

Status of non-cooperation with previous CRA:

Ratings from India Ratings were suspended in April 2016 due to lack of adequate information, and then subsequently withdrawn in December 2016. Ratings from CRISIL were also suspended in June 2015 due to SEPL's non-cooperation for review of ratings.

Any other information: None

Rating history for last three years:

Instrument	Type	Current Rating (FY2018)		Date & Rating Dec 2017	Chronology of Rating History for the past 3 years	
		Amount Rated (Rs. crore)	Amount Outstanding (Rs Crore)		Date & Rating in FY2017 Mar 2017	Date & Rating in FY2016 Dec 2015
1 Cash Credit	Long Term	50.0	NA	Withdrawn	[ICRA]BBB (Stable) ISSUER NOT COOPERATING	[ICRA]BBB (Stable)
2 Term Loans	Long Term	1.8	NA	Withdrawn	[ICRA]BBB (Stable) ISSUER NOT COOPERATING	[ICRA]BBB (Stable)
3 LC/FLC	Short Term	25.0	NA	Withdrawn	[ICRA]A3+ ISSUER NOT COOPERATING	[ICRA]A3+
4 Bank Guarantee	Short Term	(12.0)	NA	Withdrawn	[ICRA]A3+ ISSUER NOT COOPERATING	[ICRA]A3+

Complexity level of the rated instrument:

ICRA has classified various instruments based on their complexity as "Simple", "Complex" and "Highly Complex". The classification of instruments according to their complexity levels is available on the website www.icra.in

Annexure-1: Instrument Details

ISIN	Instrument Name	Date of Issuance / Sanction	Coupon Rate	Maturity Date	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Cash Credit	NA	NA	NA	50.0	[ICRA]BBB (Stable) ISSUER NOT COOPERATING withdrawn
NA	Term Loans	NA	NA	NA	1.8	[ICRA]BBB (Stable) ISSUER NOT COOPERATING withdrawn
NA	LC/FLC	NA	NA	NA	25.0	[ICRA]A3+ ISSUER NOT COOPERATING withdrawn
NA	Bank Guarantee	NA	NA	NA	(12.0)	[ICRA]A3+ ISSUER NOT COOPERATING withdrawn

Source: Scott-Edil Pharmacia Limited

ANALYST CONTACTS

Subrata Ray

+91 22 6114 3408
subrata@icraindia.com

Shamsher Dewan

+91 124 4545 328
shamsherd@icraindia.com

Sruthi Thomas

+91 124 4545 822
sruthi.thomas@icraindia.com

RELATIONSHIP CONTACT

Jayanta Chatterjee

+91 80 4332 6401
jayantac@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860
naznin.prodhani@icraindia.com

Helpline for business queries:

+91-124-3341580 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited

Corporate Office

Building No. 8, 2nd Floor, Tower A; DLF Cyber City, Phase II; Gurgaon 122 002

Tel: +91 124 4545300

Email: info@icraindia.com

Website: www.icra.in

Registered Office

1105, Kailash Building, 11th Floor; 26 Kasturba Gandhi Marg; New Delhi 110001

Tel: +91 11 23357940-50

Branches

Mumbai + (91 22) 24331046/53/62/74/86/87

Chennai + (91 44) 2434 0043/9659/8080, 2433 0724/ 3293/3294,

Kolkata + (91 33) 2287 8839 /2287 6617/ 2283 1411/ 2280 0008,

Bangalore + (91 80) 2559 7401/4049

Ahmedabad+ (91 79) 2658 4924/5049/2008

Hyderabad + (91 40) 2373 5061/7251

Pune + (91 20) 66069999

© Copyright, 2017 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents